Ascendis Pharma A/S ASND
$252.73 −$3.23 (-1.26%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $252.73 0.00%
Open$255.44
Prev close$255.96
Day range$251.55 – $256.65
Volume602.9K
Market cap$16.63B
P/E (TTM)34.7
Dividend yield–
Earnings
Average move on report day±4.2%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+13.0%
Worst reaction-11.3%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 12 Nov 2026 | Pre Market | ±5.2% | +3.00% | Within range |
| 2026/Q2 | 13 Aug 2026 | Pre Market | ±6.2% | -3.61% | Within range |
| 2026/Q1 | 7 May 2026 | Pre Market | ±7.6% | +4.34% | Within range |
| 2025/Q4 | 11 Feb 2026 | After Market | ±6.2% | -1.53% | Within range |
| 2025/Q3 | 12 Nov 2025 | After Market | ±8.2% | +3.63% | Within range |
| 2025/Q2 | 7 Aug 2025 | After Market | ±12.0% | +0.60% | Within range |
| 2025/Q1 | 1 May 2025 | After Market | ±10.4% | +2.74% | Within range |
| 2024/Q4 | 12 Feb 2025 | After Market | ±7.9% | +12.96% | Bigger than priced |
| 2024/Q3 | 14 Nov 2024 | After Market | ±21.0% | +1.79% | Within range |
| 2024/Q2 | 3 Sep 2024 | After Market | ±9.9% | -11.27% | Bigger than priced |
| 2024/Q1 | 2 May 2024 | After Market | ±21.8% | -2.76% | Within range |
| 2023/Q4 | 7 Feb 2024 | After Market | ±10.4% | -0.03% | Within range |
| 2023/Q3 | 7 Nov 2023 | After Market | ±9.5% | -1.47% | Within range |
| 2023/Q2 | 5 Sep 2023 | After Market | ±15.2% | +4.24% | Within range |
| 2023/Q1 | 27 Apr 2023 | After Market | ±19.3% | -9.12% | Within range |
| 2022/Q4 | 16 Feb 2023 | After Market | – | +4.75% | – |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q3
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026 · reported in EUR
Revenue€369.66M+73.0% YoY
Operating profit€124.58M+1,032.8% YoY
Net profit€73.97M+221.3% YoY
Diluted EPS€1.08+208.0% YoY
Free cash flow€186.03M+8,758.6% YoY
Operating cash flow€188.79M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin91.9%
Operating margin31.3%
Net margin72.9%
Return on equity132.2%
Return on assets49.0%
Return on invested capital69.9%
Current ratio2.89
Liabilities / assets38.2%
Cash & investments€964.36M
Total debt€447.81M
Net cash (debt)€516.56M
Free cash flow / sales43.1%
No comments yet — be the first to weigh in on ASND.
Sign in to join the discussion.